⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2173735 | 1.00 | — | — | |
| SCHEMBL2173922 | 1.00 | — | — | |
| SCHEMBL22639074 | 0.86 | — | — | |
| SCHEMBL1247280 | 0.85 | — | — | |
| SCHEMBL1247090 | 0.79 | — | — | |
| SCHEMBL26622171 | 0.75 | — | — | |
| SCHEMBL6829177 | 0.71 | — | — | |
| SCHEMBL3372053 | 0.71 | LRRK2 (0.30) | — | |
| SCHEMBL8891952 | 0.69 | PDE4D (0.32) | — | |
| SCHEMBL24513603 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200216419-A1 | BENZIMIDAZOLES FOR USE IN THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES | CAPELLA THERAPEUTICS, INC. | 2020-07-09 | — | — | US | claimed |
| US-10590108-B2 | Benzimidazoles for use in the treatment of cancer and inflammatory diseases | CAPELLA THERAPEUTICS, INC. (US) | 2020-03-17 | — | — | US | claimed |
| US-20180273511-A1 | BENZIMIDAZOLES FOR USE IN THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES | CAPELLA THERAPEUTICS, INC. | 2018-09-27 | — | — | US | claimed |
| WO-2017053537-A1 | BENZIMIDAZOLES FOR USE IN THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES | CAPELLA THERAPEUTICS, INC. (US) | 2017-03-30 | — | — | WO | claimed |
| US-8513186-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2013-08-20 | — | — | US | claimed |
| EP-2556056-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2013-02-13 | — | — | EP | claimed |
| US-20130023494-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2013-01-24 | — | — | US | claimed |
| WO-2011127051-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2011-10-13 | — | — | WO | claimed |
| EP-2162432-A2 | ANTIVIRAL COMPOUNDS | Gilead Sciences, Inc. (US) | 2010-03-17 | — | — | EP | claimed |
| US-20090186869-A1 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2009-07-23 | — | — | US | claimed |
| US-20090047252-A1 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2009-02-19 | — | — | US | claimed |
| WO-2009005677-A2 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2009-01-08 | — | — | WO | claimed |
| WO-2009005690-A2 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2009-01-08 | — | — | WO | claimed |
| WO-2023210623-A1 | HALOALKYL SULFONE ANILIDE COMPOUND AND HERBICIDE CONTAINING SAME | 株式会社エス・ディー・エス バイオテック | 2023-11-02 | — | — | WO | disclosed |
| US-20230271938-A1 | BENZIMIDAZOLES FOR USE IN THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES | CAPELLA THERAPEUTICS, INC. | 2023-08-31 | — | — | US | disclosed |
| CN-115916194-A | Methods for delaying, preventing and treating acquired resistance to RAS inhibitors | 锐新医药公司 | 2023-04-04 | — | — | CN | disclosed |
| US-5502027-A | ALGICIDES | ROHM AND HAAS COMPANY (US) | 1996-03-26 | — | — | US | disclosed |
| EP-0415642-B1 | Glutarimides | ROHM & HAAS (US) | 1995-12-06 | — | — | EP | disclosed |
| US-5393735-A | N-(halo-oxy-)phenyl substituted cyclic imides | ROHM AND HAAS COMPANY (US) | 1995-02-28 | — | — | US | disclosed |
| EP-0415642-A1 | Glutarimides | ROHM AND HAAS COMPANY (US) | 1991-03-06 | — | — | EP | disclosed |